Literature DB >> 29637518

Cerebrovascular Events After Continuous-Flow Left Ventricular Assist Devices.

Pouya Tahsili-Fahadan1,2, David R Curfman3, Albert A Davis3, Noushin Yahyavi-Firouz-Abadi4, Lucia Rivera-Lara1,5, Michael E Nassif6, Shane J LaRue6, Gregory A Ewald6, Allyson R Zazulia7,8.   

Abstract

BACKGROUND: Cerebrovascular events (CVE) are among the most common and serious complications after implantation of continuous-flow left ventricular assist devices (CF-LVAD). We studied the incidence, subtypes, anatomical distribution, and pre- and post-implantation risk factors of CVEs as well as the effect of CVEs on outcomes after CF-LVAD implantation at our institution.
METHODS: Retrospective analysis of clinical and neuroimaging data of 372 patients with CF-LVAD between May 2005 and December 2013 using standard statistical methods.
RESULTS: CVEs occurred in 71 patients (19%), consisting of 35 ischemic (49%), 26 hemorrhagic (37%), and 10 ischemic+hemorrhagic (14%) events. History of coronary artery disease and female gender was associated with higher odds of ischemic CVE (OR 2.84 and 2.5, respectively), and diabetes mellitus was associated with higher odds of hemorrhagic CVE (OR 3.12). While we found a higher rate of ischemic CVEs in patients not taking any antithrombotic medications, no difference was found between patients with ischemic and hemorrhagic CVEs. Occurrence of CVEs was associated with increased mortality (HR 1.62). Heart transplantation was associated with improved survival (HR 0.02). In patients without heart transplantation, occurrence of CVE was associated with decreased survival.
CONCLUSIONS: LVADs are associated with high rates of CVE, increased mortality, and lower rates of heart transplantation. Further investigations to identify the optimal primary and secondary stroke prevention measures in post-LVAD patients are warranted.

Entities:  

Keywords:  Cardiac transplant; Heart failure; Left ventricular assist device; Stroke

Mesh:

Year:  2018        PMID: 29637518     DOI: 10.1007/s12028-018-0531-y

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  27 in total

Review 1.  Bleeding and thrombosis in patients with continuous-flow ventricular assist devices.

Authors:  Peter M Eckman; Ranjit John
Journal:  Circulation       Date:  2012-06-19       Impact factor: 29.690

Review 2.  Antithrombotic therapy for left ventricular assist devices in adults: a systematic review.

Authors:  L M Baumann Kreuziger; B Kim; G M Wieselthaler
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

3.  Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device.

Authors:  Tomoko S Kato; P Christian Schulze; Jonathan Yang; Ernest Chan; Khurram Shahzad; Hiroo Takayama; Nir Uriel; Ulrich Jorde; Maryjane Farr; Yoshifumi Naka; Donna Mancini
Journal:  J Heart Lung Transplant       Date:  2011-10-08       Impact factor: 10.247

4.  Stroke After Left Ventricular Assist Device Implantation: Outcomes in the Continuous-Flow Era.

Authors:  Laura Harvey; Christopher Holley; Samit S Roy; Peter Eckman; Rebecca Cogswell; Kenneth Liao; Ranjit John
Journal:  Ann Thorac Surg       Date:  2015-06-09       Impact factor: 4.330

5.  Use of a continuous-flow device in patients awaiting heart transplantation.

Authors:  Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier
Journal:  N Engl J Med       Date:  2007-08-30       Impact factor: 91.245

6.  Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II).

Authors:  Jolanta Klovaite; Finn Gustafsson; Svend A Mortensen; Kåre Sander; Lars B Nielsen
Journal:  J Am Coll Cardiol       Date:  2009-06-09       Impact factor: 24.094

7.  Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience.

Authors:  Pierre-Yves Litzler; Hassiba Smail; Virginie Barbay; Catherine Nafeh-Bizet; François Bouchart; Jean-Marc Baste; Caroline Abriou; Jean-Paul Bessou
Journal:  Eur J Cardiothorac Surg       Date:  2013-05-12       Impact factor: 4.191

8.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

9.  Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients.

Authors:  James K Kirklin; David C Naftel; Robert L Kormos; Lynne W Stevenson; Francis D Pagani; Marissa A Miller; J T Baldwin; J Timothy Baldwin; James B Young
Journal:  J Heart Lung Transplant       Date:  2013-02       Impact factor: 10.247

10.  Thromboembolic stroke in patients with a HeartMate-II left ventricular assist device - the role of anticoagulation.

Authors:  Walter M van den Bergh; Annemieke Oude Lansink-Hartgring; Abram L van Duijn; Annemarie E Engström; Jaap R Lahpor; Arjen J C Slooter
Journal:  J Cardiothorac Surg       Date:  2015-10-15       Impact factor: 1.637

View more
  1 in total

1.  Contemporary outcomes of continuous-flow left ventricular assist devices-a systematic review.

Authors:  Nicholas McNamara; Harry Narroway; Michael Williams; John Brookes; James Farag; David Cistulli; Paul Bannon; Silvana Marasco; Evgenij Potapov; Antonio Loforte
Journal:  Ann Cardiothorac Surg       Date:  2021-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.